Literature DB >> 9291343

Utilization and cost of serologic tests for Lyme disease in Maryland.

G T Strickland1, A C Karp, A Mathews, C A Peña.   

Abstract

To ascertain use of serologic tests for Lyme disease (LD) in Maryland, all laboratories registered with the State Health Department were surveyed. Results show that from 1992 to 1995, 17 laboratories performed 100,000 serologic tests costing $7.1 million on Maryland residents; 90% of these tests were EIAs. The proportion of positive EIAs increased from 3.4% in 1992 to approximately 7.0% in 1994 and 1995, and the percentage of positive second tests (Western blot, WB) fell from 7.9% to 5.0%-5.5%. The large number of EIAs performed in comparison with the low incidence of LD in the state results in a low predictive value of a positive EIA test. Therefore, the WB is indicated to confirm equivocal and positive EIA tests when characteristic clinical findings of LD are not present. The 30,000 tests for LD performed annually on Maryland residents at a cost of over $2 million in direct medical costs must be added to the public health burden of LD in this state.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291343     DOI: 10.1086/517311

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Effects of OspA vaccination on Lyme disease serologic testing.

Authors:  M E Aguero-Rosenfeld; J Roberge; C A Carbonaro; J Nowakowski; R B Nadelman; G P Wormser
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014-2016.

Authors:  Sarah A Hook; Seonghye Jeon; Sara A Niesobecki; AmberJean P Hansen; James I Meek; Jenna K H Bjork; Franny M Dorr; Heather J Rutz; Katherine A Feldman; Jennifer L White; P Bryon Backenson; Manjunath B Shankar; Martin I Meltzer; Alison F Hinckley
Journal:  Emerg Infect Dis       Date:  2022-06       Impact factor: 16.126

3.  Lyme disease testing by large commercial laboratories in the United States.

Authors:  Alison F Hinckley; Neeta P Connally; James I Meek; Barbara J Johnson; Melissa M Kemperman; Katherine A Feldman; Jennifer L White; Paul S Mead
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

4.  Economic impact of Lyme disease.

Authors:  Xinzhi Zhang; Martin I Meltzer; César A Peña; Annette B Hopkins; Lane Wroth; Alan D Fix
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

5.  Health care costs, utilization and patterns of care following Lyme disease.

Authors:  Emily R Adrion; John Aucott; Klaus W Lemke; Jonathan P Weiner
Journal:  PLoS One       Date:  2015-02-04       Impact factor: 3.240

Review 6.  The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review.

Authors:  Stephen Mac; Sara R da Silva; Beate Sander
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.